Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced two new analyses and three encore presentations on bempedoic acid to be featured at the European Atherosclerosis Society (EAS) Congress 2026, May 24-27 in Athens.

Data include a Phase 2 pediatric HeFH study showing LDL-C reductions and CLEAR Outcomes analyses of factors linked to ≥30% LDL-C lowering and cardiovascular outcomes.

AI-generated analysis. Not financial advice.

News Market Reaction – ESPR

-0.32%

1 alert

-0.32% News Effect

On the day this news was published, ESPR declined 0.32%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Pediatric age range: 6–17 years Adult LDL-C reduction threshold: 30% or greater EAS Congress dates: May 24–27, 2026 +5 more

8 metrics

Pediatric age range 6–17 years Children in Phase 2 HeFH bempedoic acid study

Adult LDL-C reduction threshold 30% or greater CLEAR Outcomes analysis of enhanced LDL-C lowering

EAS Congress dates May 24–27, 2026 European Atherosclerosis Society Congress in Athens

Pediatric abstract time May 25, 2026; 7:35–8:35 AM EST Science-at-a-Glance Session, Station 08

Adult factors abstract time May 25, 2026; 7:35–8:35 AM EST Statin-intolerant patients LDL-C lowering analysis

VTE analysis session time May 25, 2026; 3:30–5:00 AM EST New perspectives on lipid-lowering therapies session

Stroke analysis time May 25, 2026; 6:30–7:30 AM EST Novel lipid-lowering therapies SaaG session

CV events analysis time May 25, 2026; 6:30–7:30 AM EST Secondary CLEAR Outcomes analysis without background LLT

Market Reality Check

Price: $3.12 Vol: Volume 9,061,716 is at 0....

low vol

$3.12 Last Close

Volume Volume 9,061,716 is at 0.43x the 20-day average of 20,848,549, indicating subdued trading ahead of this data-focused update. low

Technical Shares at $3.13 are trading above the 200-day MA of $2.86 and about 25.03% below the $4.175 52-week high, while sitting well above the $0.6925 52-week low.

Peers on Argus

Pre-news action among close peers was mixed: AQST (-3.48%) and SIGA (-2.2%) were...

1 Down

Pre-news action among close peers was mixed: AQST (-3.48%) and SIGA (-2.2%) were down, while EOLS (+5.18%), AKBA (+0.85%), and ORGO (+4.78%) traded higher. Only SIGA appeared in the momentum scanner, moving down without related headlines, suggesting no clear sector-wide driver tied to this announcement.

Historical Context

5 past events · Latest: May 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 01	Take-private acquisition	Positive	+55.5%	ARCHIMED affiliate agreed to acquire Esperion at cash premium with CVR.
Apr 23	Earnings call scheduling	Neutral	-3.0%	Company announced timing of Q1 2026 financial results and webcast.
Apr 02	Corstasis acquisition close	Positive	-2.3%	Closed Corstasis deal, adding FDA-approved Enbumyst nasal diuretic to portfolio.
Mar 31	Conference participation	Neutral	+4.2%	Announced participation in Needham healthcare conference with webcast access.
Mar 30	CLEAR Outcomes data	Positive	-4.0%	Presented post-hoc CLEAR Outcomes analyses showing stroke risk reduction benefits.

Pattern Detected

Recent ESPR news often showed price divergence from fundamentally positive or neutral events, including strategic deals and clinical data, with the acquisition announcement being the key exception aligning with a sharp upside move.

Recent Company History

Over the past few months, Esperion has reported several material events, including the ARCHIMED acquisition agreement on May 1, 2026 with a strong +55.5% move, and closing the Corstasis deal on April 2, 2026, which modestly weighed on shares. Neutral items like conference participation and an earnings-date notice around April 23, 2026 produced mixed reactions. Earlier CLEAR Outcomes data on March 30, 2026 was clinically positive but met a negative price response. Today’s EAS Congress announcement fits this pattern of clinically oriented updates against a backdrop of pending acquisition.

Market Pulse Summary

This announcement highlights new bempedoic acid analyses, including a pediatric Phase 2 study in HeF...

Analysis

This announcement highlights new bempedoic acid analyses, including a pediatric Phase 2 study in HeFH children aged 6–17 and CLEAR Outcomes work on ≥30% LDL-C reductions in statin-intolerant adults. It follows a series of events such as the ARCHIMED acquisition agreement and CLEAR Outcomes presentations. Investors may focus on how these data support potential pediatric Phase 3 development and clinical positioning while the company progresses toward a planned take-private transaction at $3.16 per share plus a CVR.

Key Terms

phase 2, phase 3, heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, +4 more

8 terms

phase 2 medical

"Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 3 medical

"supporting the advancement of bempedoic acid into Phase 3 development for pediatric patients..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

heterozygous familial hypercholesterolemia medical

"Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH)..."

A genetic condition where a person inherits one faulty copy of a gene that prevents the body from clearing high levels of “bad” (LDL) cholesterol, often leading to very early and persistent high cholesterol. Think of the liver’s cleanup crew as halved: cholesterol builds up more easily, raising the long-term risk of heart disease. For investors, it matters because it defines a steady, identifiable patient group for cholesterol tests, long-term therapies, new drugs and devices, and related regulatory and reimbursement decisions.

homozygous familial hypercholesterolemia medical

"Phase 3 development for pediatric patients with HeFH and homozygous familial hypercholesterolemia."

A rare inherited condition in which both copies of a person’s cholesterol‑regulating gene are faulty, causing extremely high blood cholesterol from birth and greatly increased early risk of heart disease. Think of the body’s cholesterol cleanup crew being nearly absent, so cholesterol builds up quickly; for investors this matters because it defines a small but urgent patient population that shapes demand for specialized drugs, clinical trial design, regulatory scrutiny, and potential pricing or reimbursement decisions.

ldl-c medical

"bempedoic acid products to meaningfully lower LDL-C levels and reduce the risk..."

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

venous thromboembolism medical

"The Association Between Bempedoic Acid And Risk Of Venous Thromboembolism: A Post Hoc Analysis..."

Venous thromboembolism is a medical condition in which a blood clot forms in a vein, often starting in the leg (a deep vein thrombosis) and sometimes breaking off to block blood flow in the lung (a pulmonary embolism). It matters to investors because VTE drives demand for diagnostics, treatments and hospital services, influences regulatory reviews and liability risk for healthcare firms, and can affect costs and revenue forecasts much like a sudden traffic jam disrupts movement and operations in a supply network.

post hoc analysis medical

"Venous Thromboembolism: A Post Hoc Analysis Of The CLEAR Outcomes Trial..."

Post hoc analysis is an exploratory look at data carried out after a study or trial is finished to search for patterns or effects that were not specified beforehand. Because it’s done after seeing the results, findings can arise by chance and are less reliable than preplanned tests; investors should treat post hoc claims as hypothesis-generating signals that may need confirmatory studies or regulatory review before they meaningfully affect a company’s value.

statin-intolerant medical

"Bempedoic Acid And Incidence Of Stroke Among Statin- Intolerant Patients..."

Statin-intolerant describes people who cannot take statin drugs—commonly prescribed to lower cholesterol—because they develop side effects such as persistent muscle pain, weakness, or abnormal liver test results that make continued use unsafe or impossible. For investors, statin intolerance matters because it creates a group of patients who need alternative therapies, shaping demand, pricing, and regulatory attention for newer cholesterol drugs much like shoppers forced to buy a substitute when a popular product doesn’t work for them.

AI-generated analysis. Not financial advice.

– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes –

– Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH) Congruent with Reductions in Adult Exposures –

– New Analyses from CLEAR Outcomes Trial Identified Factors Associated With Enhanced LDL-C Reductions in Adult Patients –

ANN ARBOR, Mich., May 13, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two new abstracts and three encore abstracts have been accepted for presentation at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27, 2026, in Athens, Greece.

“We are pleased to present supportive new data to the global lipid community at EAS Congress 2026, as they highlight the breadth and durability of our bempedoic acid products to meaningfully lower LDL-C levels and reduce the risk of cardiovascular events,” said Sheldon Koenig, President and CEO of Esperion. “Results from our Phase 2 pediatric study demonstrate LDL C reductions in children with heterozygous familial hypercholesterolemia are consistent with those observed in adults, supporting the advancement of bempedoic acid into Phase 3 development for pediatric patients with HeFH and homozygous familial hypercholesterolemia. These findings represent an important step toward expanding treatment options for patients with lifelong cardiovascular risk.

“In collaboration with our partner, Daiichi Sankyo Europe, we are also presenting a new analysis from the CLEAR Outcomes trial that identifies patient characteristics associated with achieving robust LDL C reductions of 30% or greater, providing additional insight into how bempedoic acid can be optimally utilized in clinical practice,” added Koenig.

Original Research

Abstract Title:    Abstract #:          Location:         Date & Time:              Session Title: Presenter:	Bempedoic Acid In Children Aged 6-17 Years With Heterozygous Familial Hypercholesterolaemia: A Phase 2 Study 178 Station 08 May 25, 2026; 7:35-8:35 AM EST Science-at-a-Glance (SaaG) Session: Real-World Lipid-Lowering Therapies and Determinants of Treatment Success Samuel S Gidding, MD
Abstract Title:  Abstract #:          Location:         Date & Time: Session Title: Presenter:	Factors Associated With Enhanced LDL-Cholesterol Lowering With Bempedoic Acid Among Statin-Intolerant Patients From CLEAR Outcomes 338 Station 08 May 25, 2026; 7:35-8:35 AM EST SaaG Session: Real-World Lipid-Lowering Therapies and Determinants of Treatment Success Christie M Ballantyne, MD

Encore Presentations

Abstract Title:    Session ID:                  Location: Date & Time:           Session Title: Presenter:	The Association Between Bempedoic Acid And Risk Of Venous Thromboembolism: A Post Hoc Analysis Of The CLEAR Outcomes Trial 122 Elisaf Hall May 25, 2026; 3:30-5:00 AM EST New perspectives on lipid lowering therapies Prof. Stephen J Nicholls, MBBS, PhD
Abstract Title:    Abstract #:                  Location Date & Time:              Session Title: Presenter:	Bempedoic Acid And Incidence Of Stroke Among Statin- Intolerant Patients: An Analysis Of The CLEAR Outcomes Trial 481 Station 07 May 25, 2026; 6:30-7:30 AM EST SaaG Session: Novel Lipid-Lowering Therapies: Clinical Outcomes and Real-World Evidence Prof. Stephen J Nicholls, MBBS, PhD
Abstract Title:    Abstract #:                  Location Date & Time:              Session Title: Presenter:	Bempedoic Acid Without Background LLT, LDL Cholesterol And Cardiovascular Events: A Secondary Analysis Of The CLEAR Outcomes Trial 455 Station 07 May 25, 2026; 6:30-7:30 AM EST SaaG Session: Novel Lipid-Lowering Therapies: Clinical Outcomes and Real-World Evidence Prof. Kausik K Ray, MD

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

What did Esperion (ESPR) announce about bempedoic acid at EAS Congress 2026?

Esperion announced two new analyses and three encore presentations on bempedoic acid for EAS Congress 2026. According to Esperion, these cover pediatric Phase 2 LDL-C reductions and CLEAR Outcomes analyses on LDL-C lowering, venous thromboembolism, stroke and cardiovascular events.

How did bempedoic acid affect LDL-C in the Phase 2 pediatric HeFH study for ESPR?

Bempedoic acid reduced LDL-C in children aged 6-17 years with heterozygous familial hypercholesterolemia. According to Esperion, pediatric LDL-C reductions were congruent with those seen in adults, supporting advancement into Phase 3 development for pediatric HeFH and homozygous familial hypercholesterolemia.

What factors associated with enhanced LDL-C reduction were found in CLEAR Outcomes for ESPR?

A new CLEAR Outcomes analysis examined which patient characteristics achieve LDL-C reductions of 30% or greater with bempedoic acid. According to Esperion, this focuses on statin-intolerant adults and aims to inform how bempedoic acid may be optimally used in clinical practice.

Which encore analyses of CLEAR Outcomes with bempedoic acid will Esperion present at EAS 2026?

Encore presentations analyze venous thromboembolism risk, stroke incidence, and cardiovascular events with bempedoic acid. According to Esperion, these post hoc and secondary CLEAR Outcomes analyses explore safety and outcomes, including use without background lipid-lowering therapy and links to LDL cholesterol.

When and where will Esperion present its bempedoic acid data at EAS Congress 2026?

Esperion’s abstracts are scheduled on May 25, 2026, in various EAS sessions in Athens, Greece. According to Esperion, presentations occur in Science-at-a-Glance and New Perspectives sessions, with morning and afternoon time slots noted in the program.

What does Esperion’s EAS 2026 presence suggest for ESPR’s cardiometabolic pipeline?

The EAS 2026 presentations highlight ongoing clinical characterization of bempedoic acid in adults and children. According to Esperion, these data support its ACLY biology focus and may inform future development in cardiometabolic indications and pediatric familial hypercholesterolemia.